
Spinout News
Quell Therapeutics signs a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialise engineered Treg cell therapies for autoimmune diseases
Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that it has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialise autologous, engineered Treg cell therapies for two autoimmune disease indications.